视黄酸受体β（RARB）和 CDKN2（p16/MTS1）启动子高甲基化在前列腺癌中的预后价值。
Prognostic Value of Promoter Hypermethylation of Retinoic Acid Receptor Beta (RARB) and CDKN2 (p16/MTS1) in Prostate Cancer.
机构信息
Department of Radiation Oncology, Imam Hossein Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran;
出版信息
Chin J Cancer Res. 2011 Dec;23(4):306-11. doi: 10.1007/s11670-011-0306-x.
OBJECTIVE
The molecular mechanism of prostate cancer is poorly understood. The aim of the study was to investigate the prevalence and prognostic value of promoter hypermethylation of retinoic acid receptor beta (RARB) and p16 among benign prostatic hyperplasia (BPH) and prostate cancer patients.
METHODS
In this case-control study, 63 patients were included in three groups; 21 with BPH as the control group, 21 with prostate cancer and good prognostic factors (based on prostate-specific antigen, Gleason score and stage) as good prognosis group, and 21 with prostate cancer and poor prognostic features as poor prognosis group. The prostate biopsy specimen of each individual was examined for hypermethylation of RARB and p16 promoters by methylation specific PCR (MSPCR).
RESULTS
Seven (33.3%) patients with good prognosis and 15 (71.4%) patients with poor prognosis were positive for RARB methylation, which were significantly higher than controls (P<0.0001). p16 promoter methylation was shown in 19.0% and 47.6% patients with good and poor prognosis, respectively. The RARB and p16 promoter methylation in the poor prognosis group was significantly higher than that in the good prognosis group (P =0.02 for RARB and P<0.0001 for p16).
CONCLUSION
Hypermethylation of RARB and p16 promoters may predict prognosis in prostate cancer.
目的
前列腺癌的分子机制尚不清楚。本研究旨在探讨维甲酸受体β（RARB）和 p16 启动子高甲基化在良性前列腺增生（BPH）和前列腺癌患者中的流行情况及其预后价值。
方法
在这项病例对照研究中，将 63 名患者分为三组：21 名 BPH 患者作为对照组，21 名前列腺癌且具有良好预后因素（基于前列腺特异性抗原、Gleason 评分和分期）的患者作为预后良好组，以及 21 名前列腺癌且具有不良预后特征的患者作为预后不良组。采用甲基化特异性 PCR（MSPCR）检测每位患者前列腺活检标本中 RARB 和 p16 启动子的高甲基化情况。
结果
7 名（33.3%）预后良好的患者和 15 名（71.4%）预后不良的患者的 RARB 甲基化呈阳性，明显高于对照组（P<0.0001）。p16 启动子甲基化在预后良好组和预后不良组中分别为 19.0%和 47.6%。预后不良组的 RARB 和 p16 启动子甲基化明显高于预后良好组（RARB 为 P =0.02，p16 为 P<0.0001）。
结论
RARB 和 p16 启动子的高甲基化可能预测前列腺癌的预后。
Zotero 插件